Healthcare Industry News: Transdermal
News Release - October 2, 2007
Mylan Announces Management of Specialty Business, Dey L.P.PITTSBURGH, Oct. 2 (HSMN NewsFeed) -- Mylan Inc. (NYSE: MYL ) announced today the management transition plan at Dey L.P., Mylan's specialty pharmaceutical business. As part of Merck Generics' integration into Mylan, Carolyn Myers, Ph.D. has been appointed President-Elect of Dey and Christy Taylor has been promoted to Chief Operating Officer, Dey.
Dr. Myers currently serves as President of Mylan Technologies, a position she has held since February 2006. While at Mylan Technologies, Dr. Myers has overseen the design, development and manufacture of Mylan's Transdermal drug delivery system. She first joined Mylan in 2003 as Vice President of Branded Business Development and Strategic Marketing. Prior to joining Mylan, Dr. Myers served as Global Director Cardiovascular at Pharmacia Inc.
Ms. Taylor initially joined Dey in 2002, most recently serving as Executive Vice President of sales, marketing, business development and government affairs. In this role, she has directed marketing, Dey's three sales teams, sales operations, as well as the business development activities of the Company. In addition, Ms. Taylor has led the government affairs efforts on behalf of Dey. Before joining Dey, Ms. Taylor was vice chairman of Nelson Professional Sales, a provider of integrated selling solutions to the pharmaceutical industry.
Mylan's Vice Chairman and CEO Robert J. Coury commented: "Carolyn has been a valuable addition to the Mylan team since joining us four years ago to oversee our brand development strategy and, most recently, our extremely successful Transdermal business. Her strong leadership skills and balanced background in science, marketing and business development make her ideally suited to lead Mylan's specialty division."
Dr. Myers said: "I am pleased to be taking on this new position within Mylan. Dey's industry-leading respiratory business will form the base of a strong specialty division, which is highly complimentary to the new Mylan. I look forward to working with Christy and the other members of Dey's senior management team to take this already strong business to a new level."
Mr. Coury continued: "Christy is an outstanding individual and leader, who has played a pivotal part in the development of Dey's business. Combining Carolyn's background with Christy's general management expertise and intimate knowledge of Dey will ensure that Mylan effectively and efficiently capitalizes on the business opportunities in the global specialty pharmaceutical industry."
Ms. Taylor commented: "I am excited to be taking on this new expanded role within Dey. Over the past few months, I have had the privilege to get to know Carolyn and other members of the Mylan senior management team and am excited by the fact that we share a similar culture, values, and a commitment to creating a strong specialty business. "
As part of the management integration, Mel Engle, Dey's current President and Chief Executive Officer, will step down. Mr. Engle will remain President of Dey until December 31, 2007 at which point he will be formally succeeded by Dr. Myers. Ms. Taylor's new position as Chief Operating Officer of Dey will take effect immediately. During the transition, Dr. Myers will also continue to oversee Mylan Technologies.
Dr. Myers received her Ph.D. from the University of British Columbia, Canada, a post-doctorate degree from the University of Wisconsin and a Master's in Business Administration from Rutgers University.
Ms. Taylor earned her Bachelor of Science in Business from St. Mary's College, and her Master's in International Business from the American Graduate School of International Management.
Mylan Inc. is one of the world's leading quality generic and specialty pharmaceutical companies. The Company offers one of the industry's broadest and highest quality product portfolios, a robust product pipeline and a global commercial footprint through operations in more than 90 countries. Through its controlling interest in Matrix Laboratories Limited, Mylan has direct access to one of the largest active pharmaceutical ingredient (API) manufacturers in the world. Dey L.P., Mylan's fully integrated specialty business, provides the Company with innovative and diversified opportunities in the respiratory and allergy therapeutic areas.
For more information about Mylan, please visit www.mylan.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsMylan and Upjohn, a Division of Pfizer, to Combine, Creating a New Champion for Global Health Uniquely Positioned to Fulfill the World's Need for Medicine
Statement from Mylan's Board of Directors Regarding Retirement of CEO and Board Member Heather Bresch in Conjunction with the Combination of Mylan and Upjohn, a Division of Pfizer
Mylan Launches Generic Suboxone(R) Sublingual Film to Treat Opioid Dependence